219 results on '"Anaissie, E. J."'
Search Results
2. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model
3. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients
4. Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients
5. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
6. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
7. Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients
8. Treatment of 21 Cases of Invasive Mucormycosis with Amphotericin B Colloidal Dispersion
9. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
10. Predictors of outcome in cancer patients with candidemia
11. Activated lymphocytes reduce adherence of Aspergillus fumigatus
12. Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy
13. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
14. Emerging fungal pathogens
15. Atypical B12 Deficiency with Nonresolving Paraesthesia
16. Chronic systemic candidiasis
17. Bortezomib (BZB)-associated adverse events (AE) in patients with multiple myeloma (MM).
18. Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols.
19. Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM).
20. Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
21. Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC).
22. The Arkansas experience with autotransplantation (AT) for older patients (OP, age > 65) with multiple myeloma (MM).
23. Predictors of deep vein thrombosis (DVT) in newly diagnosed multiple myeloma (MM) patients with and without prophylactic recombinant erythropoietin (EPO) therapy
24. Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2
25. Randomized, dose-defined, phase 1B study of recombinant human mannose-binding lectin (rhMBL, EZN-2232) in patients with multiple myeloma undergoing high-dose chemotherapy
26. Trial Design for Mold-Active Agents: Time to Break the Mold--Aspergillosis in Neutropenic Adults
27. When a Paradoxical Increase in Serum Galactomannan Antigen during Caspofungin Therapy Is Not Paradoxical after All
28. Benefits of exercise in combination with epoetin alfa for multiple myeloma
29. Are Antimicrobial-Impregnated Catheters Effective? Replace the Water and Grab Your Washcloth, Because We Have a Baby to Wash
30. Reply
31. Incidence of Imipenem Hypersensitivity Reactions in Febrile Neutropenic Bone Marrow Transplant Patients with a History of Penicillin Allergy
32. Optimizing Voriconazole Susceptibility Testing of Candida : Effects of Incubation Time, Endpoint Rule, Species of Candida , and Level of Fluconazole Susceptibility
33. Treatment of Murine Fusariosis with SCH 56592
34. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
35. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis
36. Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the Literature
37. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study
38. Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans
39. Septic Prepatellar Bursitis Caused by Stenotrophomonas (Xanthomonas) maltophilia
40. Stenotrophomonas maltophilia: An Unusual Cause of Biliary Sepsis
41. Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections
42. Detection of amphotericin B-resistant Candida isolates in a broth-based system
43. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice
44. Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography
45. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections
46. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice
47. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis
48. Taxonomy, biology, and clinical aspects of Fusarium species
49. Correlation between In Vitro and In Vivo Activity of Antifungal Agents against Candida Species
50. Infections Due to Cunninghamella bertholletiae in Patients with Cancer: Report of Three Cases and Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.